Is lumateperone (Caplyta®) really different from other atypical antipsychotics?

This article was published on June 17, 2022. It was last updated on June 19, 2022. Lumateperone (US brand name Caplyta®) is a second-generation (“atypical”) antipsychotic that was approved by the FDA in 2019 and became available in the US in 2020. For basic information about this medication, please see the following article on this…